Gene expression signature of atypical breast hyperplasia and regulation by SFRP1
Abstract Background Atypical breast hyperplasias (AH) have a 10-year risk of progression to invasive cancer estimated at 4–7%, with the overall risk of developing breast cancer increased by ~ 4-fold. AH lesions are estrogen receptor alpha positive (ERα+) and represent risk indicators and/or precurso...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13058-019-1157-5 |
id |
doaj-14367b64f7854897a6a4e3a757b9c8bf |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kelly J. Gregory Amy L. Roberts Erin M. Conlon Jacob A. Mayfield Mary J. Hagen Giovanna M. Crisi Brooke A. Bentley Jeffrey J. Kane Grace Makari-Judson Holly S. Mason Jun Yu Lihua Julie Zhu Karl Simin Jacob P. S. Johnson Ashraf Khan Ben R. Schneider Sallie S. Schneider D. Joseph Jerry |
spellingShingle |
Kelly J. Gregory Amy L. Roberts Erin M. Conlon Jacob A. Mayfield Mary J. Hagen Giovanna M. Crisi Brooke A. Bentley Jeffrey J. Kane Grace Makari-Judson Holly S. Mason Jun Yu Lihua Julie Zhu Karl Simin Jacob P. S. Johnson Ashraf Khan Ben R. Schneider Sallie S. Schneider D. Joseph Jerry Gene expression signature of atypical breast hyperplasia and regulation by SFRP1 Breast Cancer Research Atypical hyperplasia Breast Lobular Ductal Premalignancy SFRP1 |
author_facet |
Kelly J. Gregory Amy L. Roberts Erin M. Conlon Jacob A. Mayfield Mary J. Hagen Giovanna M. Crisi Brooke A. Bentley Jeffrey J. Kane Grace Makari-Judson Holly S. Mason Jun Yu Lihua Julie Zhu Karl Simin Jacob P. S. Johnson Ashraf Khan Ben R. Schneider Sallie S. Schneider D. Joseph Jerry |
author_sort |
Kelly J. Gregory |
title |
Gene expression signature of atypical breast hyperplasia and regulation by SFRP1 |
title_short |
Gene expression signature of atypical breast hyperplasia and regulation by SFRP1 |
title_full |
Gene expression signature of atypical breast hyperplasia and regulation by SFRP1 |
title_fullStr |
Gene expression signature of atypical breast hyperplasia and regulation by SFRP1 |
title_full_unstemmed |
Gene expression signature of atypical breast hyperplasia and regulation by SFRP1 |
title_sort |
gene expression signature of atypical breast hyperplasia and regulation by sfrp1 |
publisher |
BMC |
series |
Breast Cancer Research |
issn |
1465-542X |
publishDate |
2019-06-01 |
description |
Abstract Background Atypical breast hyperplasias (AH) have a 10-year risk of progression to invasive cancer estimated at 4–7%, with the overall risk of developing breast cancer increased by ~ 4-fold. AH lesions are estrogen receptor alpha positive (ERα+) and represent risk indicators and/or precursor lesions to low grade ERα+ tumors. Therefore, molecular profiles of AH lesions offer insights into the earliest changes in the breast epithelium, rendering it susceptible to oncogenic transformation. Methods In this study, women were selected who were diagnosed with ductal or lobular AH, but no breast cancer prior to or within the 2-year follow-up. Paired AH and histologically normal benign (HNB) tissues from patients were microdissected. RNA was isolated, amplified linearly, labeled, and hybridized to whole transcriptome microarrays to determine gene expression profiles. Genes that were differentially expressed between AH and HNB were identified using a paired analysis. Gene expression signatures distinguishing AH and HNB were defined using AGNES and PAM methods. Regulation of gene networks was investigated using breast epithelial cell lines, explant cultures of normal breast tissue and mouse tissues. Results A 99-gene signature discriminated the histologically normal and AH tissues in 81% of the cases. Network analysis identified coordinated alterations in signaling through ERα, epidermal growth factor receptors, and androgen receptor which were associated with the development of both lobular and ductal AH. Decreased expression of SFRP1 was also consistently lower in AH. Knockdown of SFRP1 in 76N-Tert cells resulted altered expression of 13 genes similarly to that observed in AH. An SFRP1-regulated network was also observed in tissues from mice lacking Sfrp1. Re-expression of SFRP1 in MCF7 cells provided further support for the SFRP1-regulated network. Treatment of breast explant cultures with rSFRP1 dampened estrogen-induced progesterone receptor levels. Conclusions The alterations in gene expression were observed in both ductal and lobular AH suggesting shared underlying mechanisms predisposing to AH. Loss of SFRP1 expression is a significant regulator of AH transcriptional profiles driving previously unidentified changes affecting responses to estrogen and possibly other pathways. The gene signature and pathways provide insights into alterations contributing to AH breast lesions. |
topic |
Atypical hyperplasia Breast Lobular Ductal Premalignancy SFRP1 |
url |
http://link.springer.com/article/10.1186/s13058-019-1157-5 |
work_keys_str_mv |
AT kellyjgregory geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT amylroberts geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT erinmconlon geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT jacobamayfield geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT maryjhagen geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT giovannamcrisi geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT brookeabentley geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT jeffreyjkane geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT gracemakarijudson geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT hollysmason geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT junyu geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT lihuajuliezhu geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT karlsimin geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT jacobpsjohnson geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT ashrafkhan geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT benrschneider geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT salliesschneider geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 AT djosephjerry geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1 |
_version_ |
1721569433299714048 |
spelling |
doaj-14367b64f7854897a6a4e3a757b9c8bf2021-04-02T12:19:37ZengBMCBreast Cancer Research1465-542X2019-06-0121111810.1186/s13058-019-1157-5Gene expression signature of atypical breast hyperplasia and regulation by SFRP1Kelly J. Gregory0Amy L. Roberts1Erin M. Conlon2Jacob A. Mayfield3Mary J. Hagen4Giovanna M. Crisi5Brooke A. Bentley6Jeffrey J. Kane7Grace Makari-Judson8Holly S. Mason9Jun Yu10Lihua Julie Zhu11Karl Simin12Jacob P. S. Johnson13Ashraf Khan14Ben R. Schneider15Sallie S. Schneider16D. Joseph Jerry17Pioneer Valley Life Sciences InstituteDepartment of Veterinary and Animal Sciences, University of Massachusetts-AmherstDepartment of Mathematics and Statistics, University of MassachusettsDivision of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical SchoolDepartment of Veterinary and Animal Sciences, University of Massachusetts-AmherstDepartment of Pathology, University of Massachusetts Medical School/BaystateDepartment of Pathology, University of Massachusetts Medical School/BaystatePioneer Valley Life Sciences InstituteDivision of Hematology-Oncology, University of Massachusetts Medical School/BaystateDepartment of Surgery, University of Massachusetts Medical School/BaystateUniversity of Massachusetts Medical School, Molecular, Cell, and Cancer BiologyUniversity of Massachusetts Medical School, Molecular, Cell, and Cancer BiologyUniversity of Massachusetts Medical School, Molecular, Cell, and Cancer BiologyUniversity of Massachusetts Medical School, Molecular, Cell, and Cancer BiologyDepartment of Pathology, University of Massachusetts Medical SchoolPioneer Valley Life Sciences InstitutePioneer Valley Life Sciences InstitutePioneer Valley Life Sciences InstituteAbstract Background Atypical breast hyperplasias (AH) have a 10-year risk of progression to invasive cancer estimated at 4–7%, with the overall risk of developing breast cancer increased by ~ 4-fold. AH lesions are estrogen receptor alpha positive (ERα+) and represent risk indicators and/or precursor lesions to low grade ERα+ tumors. Therefore, molecular profiles of AH lesions offer insights into the earliest changes in the breast epithelium, rendering it susceptible to oncogenic transformation. Methods In this study, women were selected who were diagnosed with ductal or lobular AH, but no breast cancer prior to or within the 2-year follow-up. Paired AH and histologically normal benign (HNB) tissues from patients were microdissected. RNA was isolated, amplified linearly, labeled, and hybridized to whole transcriptome microarrays to determine gene expression profiles. Genes that were differentially expressed between AH and HNB were identified using a paired analysis. Gene expression signatures distinguishing AH and HNB were defined using AGNES and PAM methods. Regulation of gene networks was investigated using breast epithelial cell lines, explant cultures of normal breast tissue and mouse tissues. Results A 99-gene signature discriminated the histologically normal and AH tissues in 81% of the cases. Network analysis identified coordinated alterations in signaling through ERα, epidermal growth factor receptors, and androgen receptor which were associated with the development of both lobular and ductal AH. Decreased expression of SFRP1 was also consistently lower in AH. Knockdown of SFRP1 in 76N-Tert cells resulted altered expression of 13 genes similarly to that observed in AH. An SFRP1-regulated network was also observed in tissues from mice lacking Sfrp1. Re-expression of SFRP1 in MCF7 cells provided further support for the SFRP1-regulated network. Treatment of breast explant cultures with rSFRP1 dampened estrogen-induced progesterone receptor levels. Conclusions The alterations in gene expression were observed in both ductal and lobular AH suggesting shared underlying mechanisms predisposing to AH. Loss of SFRP1 expression is a significant regulator of AH transcriptional profiles driving previously unidentified changes affecting responses to estrogen and possibly other pathways. The gene signature and pathways provide insights into alterations contributing to AH breast lesions.http://link.springer.com/article/10.1186/s13058-019-1157-5Atypical hyperplasiaBreastLobularDuctalPremalignancySFRP1 |